Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EEC 2022 | Advances in GABA derivatives for the treatment of epilepsy

Reetta Kälviäinen, MD, PhD, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland, talks on the use of drugs targeting the GABAergic system, specifically vigabatrin and tiagabine, for the treatment of epilepsy. Although these drugs are effective at treating epileptic seizures and infantile spasms, and are the first-line drug for the treatment of tuberous sclerosis, they have several serious adverse effects. There is therefore a great need to develop novel drugs which target the GABAergic system but do not have adverse effects. This interview took place at the 14th European Epilepsy Congress (EEC) 2022 in Geneva, Switzerland.